. . . . . "Desacetylvinblastine amide"@en . . . "approved"@en . . . . . . . . . . . . . " "@en . . . "Humans and other mammals"@en . . . . . . . "53643-48-4"@en . . . . . . . "Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols). [PubChem]"@en . . . . . . "65-75%"@en . . "24 hours."@en . "For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis"@en . " "@en . "Stanislaw Rolski, \"Method of preparing vindesine sulfate.\" U.S. Patent US4259242, issued September, 1965."@en . "3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine"@en . "Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase."@en . "3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine"@en . . . "Vindesine"@en . .